

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

Moderna Therapeutics, Inc.

Petitioner

v.

Protiva Biotherapeutics, Inc.

Patent Owner

---

Case No. IPR2019-00554

U.S. Patent No. 8,058,069

---

**DECLARATION OF THOMAS J. ANCHORDOQUY, PH.D.  
IN SUPPORT OF PETITIONER'S REPLY TO PATENT OWNER'S  
RESPONSE**

Mail Stop: PATENT BOARD  
Patent Trial and Appeal Board  
U.S. Patent & Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TABLE OF CONTENTS**

	<b><u>Page</u></b>
I. INTRODUCTION .....	1
II. SUMMARY OF OPINIONS .....	2
III. QUALIFICATION AND EXPERIENCE .....	3
IV. LEVEL OF SKILL IN THE ART .....	8
V. CLAIM CONSTRUCTION.....	9
VI. THE INSTITUTED GROUNDS.....	14
A. An Overlapping Phospholipid Range Is Disclosed .....	15
B. The Same Four Lipid-Component Carrier Particles Are Disclosed .....	18
C. Lipid-Carrier Particles Are Amenable To Routine Optimization.....	20
D. Dependent claims.....	48
VII. SECONDARY CONSIDERATIONS CANNOT OVERCOME PETITIONER’S OBVIOUSNESS SHOWING .....	53
A. The Test Data Is Not Commensurate With The Scope Of The Claims .....	53
B. Test Data Does Not Show Unexpected Results.....	54
C. Other Secondary Considerations Lack The Required Nexus Or Are Attributable To The Prior Art .....	58
VIII. CONCLUSION .....	62

Case No. IPR2019-00554  
U.S. Patent No. 8,058,069

I, Dr. Thomas J. Anchordoquy, PhD, declare as follows:

## **I. INTRODUCTION**

1. I am a tenured Professor in the Department of Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. I have been retained by counsel for ModernaTX, Inc. (“Moderna”) as an expert in the relevant art.

2. I understand that Moderna formerly engaged Dr. Andrew Janoff as an expert in this matter and that he submitted a declaration dated January 2, 2019 (“Janoff Declaration”) in support of Moderna’s Petition for Inter Partes Review (“IPR”) of U.S. Patent No. 8,058,069 (the “’069 patent”) (“Petition”). EX1008. I understand that Dr. Janoff passed away in December 2019 and that I have been engaged to replace him as Moderna’s expert in this proceeding.

3. I have reviewed Dr. Janoff’s declaration and, while I may have emphasized different points or stated things differently, I agree with the general premises set-forth regarding the invalidity of the ’069 patent as stated therein.

4. On November 13, 2019, Patent Owner Protiva Biotherapeutics, Inc. (“Patent Owner”) filed its response to Moderna’s Petition (“Response”). I have been asked to provide additional explanation regarding the prior art and the state of the art in response to Patent Owner’s arguments in its Response.

While counsel for Moderna has assisted in the preparation of this declaration (*e.g.*, aiding in formatting and providing introductory language and legal standards), the substantive opinions discussed herein are my own.

5. This declaration is based on the information currently available to me. To the extent that additional information becomes available, I reserve the right to continue my investigation and study, which may include a review of documents and information that may be produced, as well as testimony from depositions.

## II. SUMMARY OF OPINIONS

6. I understand that the Board ordered an IPR over the '069 patent with respect to the following grounds of unpatentability for claims 1-22:

- A. Under §102 and §103 in view of either the '196 PCT and '189 publication;
- B. Under §103 in view of each of the '196 PCT and '189 publication in view of Lin and/or Ahmad; and,
- C. Under §102 or §103 in view of the '554 publication.

7. The '069 patent is directed to a nucleic acid-lipid particle comprising four lipid components (*i.e.*, a cationic lipid, cholesterol, a phospholipid and a conjugated lipid), each of which fall within a claimed proportion with regard to the total lipid in the particles. *See, e.g.*, EX1001, cl.

Case No. IPR2019-00554  
U.S. Patent No. 8,058,069

1. In my opinion, Moderna has shown that the cited prior art in Grounds 1-3 renders each of the claims in the '069 patent invalid by a preponderance of the evidence.

### **III. QUALIFICATION AND EXPERIENCE**

8. I possess the knowledge, skills, experience, training and the education to form an expert opinion and testimony in this case.

9. I received a bachelor of science in biology from Oregon State University in 1982. I received my master's and doctoral degrees from the University of California Davis in Zoology in 1988 and 1989, respectively. I did my doctoral thesis work under the direction of Dr. John Crowe at the University of California Davis. Dr. Crowe is an expert in the stability of liposomes during freezing and drying, and this was the main topic of my thesis work.

10. I continued my studies at the University of Colorado as a post-doctoral researcher with Dr. John Carpenter in the University of Colorado School of Pharmacy, where I joined the faculty as an Assistant Professor in Pharmaceutical Sciences in 1998. I was promoted to Associate Professor in Pharmaceutical Sciences in 1998. I was promoted to Associate Professor in Pharmaceutical Sciences with Tenure in 2005, and then to Full Professor in 2011.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.